Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Co. stock logo
GKOS
Glaukos
$110.45
+2.6%
$94.66
$54.38
$111.39
$5.56B1.08640,346 shs322,589 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$10.65
-4.7%
$11.21
$3.89
$14.75
$248.89M1.16482,905 shs228,063 shs
Luminex Co. stock logo
LMNX
Luminex
$36.99
$36.90
$20.61
$41.69
$1.75B0.56873,093 shsN/A
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
$21.03
+3.0%
$17.94
$6.08
$37.99
$829.47M1.43779,677 shs490,904 shs
The Beauty Health Company stock logo
SKIN
Beauty Health
$2.74
-23.7%
$3.70
$1.35
$10.98
$338.20M1.132.51 million shs6.58 million shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Co. stock logo
GKOS
Glaukos
+0.68%+2.39%+6.37%+11.85%+81.92%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+1.64%-6.91%-3.87%+65.88%-90.41%
Luminex Co. stock logo
LMNX
Luminex
0.00%0.00%0.00%0.00%0.00%
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
+6.14%+7.99%+11.90%+22.00%-43.32%
The Beauty Health Company stock logo
SKIN
Beauty Health
+4.66%+11.15%-6.75%+25.52%-65.01%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Co. stock logo
GKOS
Glaukos
3.5739 of 5 stars
2.41.00.04.43.72.50.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.871 of 5 stars
3.33.00.04.62.60.00.6
Luminex Co. stock logo
LMNX
Luminex
N/AN/AN/AN/AN/AN/AN/AN/A
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
2.4263 of 5 stars
1.12.00.04.33.21.70.6
The Beauty Health Company stock logo
SKIN
Beauty Health
3.3237 of 5 stars
4.02.00.00.03.23.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Co. stock logo
GKOS
Glaukos
2.82
Moderate Buy$108.64-1.64% Downside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.67
Moderate Buy$96.00801.41% Upside
Luminex Co. stock logo
LMNX
Luminex
N/AN/AN/AN/A
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
2.18
Hold$22.557.21% Upside
The Beauty Health Company stock logo
SKIN
Beauty Health
1.92
Reduce$6.43134.62% Upside

Current Analyst Ratings

Latest SKIN, GKOS, INO, SILK, and LMNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2024
The Beauty Health Company stock logo
SKIN
Beauty Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$3.00 ➝ $2.50
5/6/2024
Glaukos Co. stock logo
GKOS
Glaukos
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$84.00 ➝ $125.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $112.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$108.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $125.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$103.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$108.00 ➝ $113.00
5/1/2024
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$19.00 ➝ $21.00
5/1/2024
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$18.00 ➝ $20.00
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
4/8/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Co. stock logo
GKOS
Glaukos
$326.43M17.04N/AN/A$9.46 per share11.68
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$832.01K299.14N/AN/A$5.16 per share2.06
Luminex Co. stock logo
LMNX
Luminex
$417.40M4.19$1.12 per share32.98$11.13 per share3.32
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
$185.49M4.47N/AN/A$3.88 per share5.42
The Beauty Health Company stock logo
SKIN
Beauty Health
$398M0.85N/AN/A$0.48 per share5.71

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.88N/AN/AN/A-43.15%-24.69%-12.27%8/7/2024 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$7.56N/AN/AN/A-16,238.91%-79.86%-57.71%5/13/2024 (Confirmed)
Luminex Co. stock logo
LMNX
Luminex
$15.17M$0.3272.5330.83N/A5.39%4.66%2.91%N/A
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
-$55.74M-$1.37N/AN/AN/A-29.02%-35.12%-20.45%8/6/2024 (Estimated)
The Beauty Health Company stock logo
SKIN
Beauty Health
-$100.12M-$0.77N/A137.00N/A-25.65%-18.85%-2.21%8/14/2024 (Estimated)

Latest SKIN, GKOS, INO, SILK, and LMNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$1.08N/A+$1.08N/AN/AN/A  
5/9/2024Q1 2024
The Beauty Health Company stock logo
SKIN
Beauty Health
-$0.14-$0.10+$0.04-$0.10$80.56 million$81.40 million    
5/1/2024Q1 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.58-$0.70-$0.12-$0.58$79.60 million$85.60 million    
4/30/2024Q1 2024
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
-$0.40-$0.36+$0.04-$0.36$44.67 million$48.50 million      
3/12/2024Q4 2023
The Beauty Health Company stock logo
SKIN
Beauty Health
-$0.11-$0.07+$0.04-$0.07$87.22 million$96.80 million    
2/28/2024Q4 2023
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
-$0.40-$0.33+$0.07-$0.33$42.23 million$47.27 million    
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Luminex Co. stock logo
LMNX
Luminex
$0.401.08%N/A125.00%N/A
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
N/AN/AN/AN/AN/A
The Beauty Health Company stock logo
SKIN
Beauty Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Co. stock logo
GKOS
Glaukos
0.78
5.38
4.68
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.60
3.60
Luminex Co. stock logo
LMNX
Luminex
0.52
8.37
6.08
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
0.50
7.95
6.97
The Beauty Health Company stock logo
SKIN
Beauty Health
12.43
6.07
5.28

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Luminex Co. stock logo
LMNX
Luminex
87.76%
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
N/A
The Beauty Health Company stock logo
SKIN
Beauty Health
93.26%

Insider Ownership

CompanyInsider Ownership
Glaukos Co. stock logo
GKOS
Glaukos
6.40%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50%
Luminex Co. stock logo
LMNX
Luminex
6.60%
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
6.70%
The Beauty Health Company stock logo
SKIN
Beauty Health
41.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90750.37 million46.98 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
12223.37 million22.79 millionOptionable
Luminex Co. stock logo
LMNX
Luminex
1,32547.31 millionN/AOptionable
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
47439.44 million36.80 millionOptionable
The Beauty Health Company stock logo
SKIN
Beauty Health
881123.43 million71.96 millionOptionable

SKIN, GKOS, INO, SILK, and LMNX Headlines

SourceHeadline
How Lindsay Arnold Maintains Her Smile and Takes Care of Her Skin: ‘Beauty Comes From Within’ (Exclusive)How Lindsay Arnold Maintains Her Smile and Takes Care of Her Skin: ‘Beauty Comes From Within’ (Exclusive)
usmagazine.com - May 10 at 5:33 PM
The Beauty Health Company (NASDAQ:SKIN) Q1 2024 Earnings Call TranscriptThe Beauty Health Company (NASDAQ:SKIN) Q1 2024 Earnings Call Transcript
msn.com - May 10 at 5:33 PM
Maybelline New York, WHO Foundation partner on mental health services accessMaybelline New York, WHO Foundation partner on mental health services access
drugstorenews.com - May 10 at 12:32 PM
Beauty Health (NASDAQ:SKIN) Price Target Cut to $2.50 by Analysts at Piper SandlerBeauty Health (NASDAQ:SKIN) Price Target Cut to $2.50 by Analysts at Piper Sandler
marketbeat.com - May 10 at 9:35 AM
Blind date: ‘I really wish I asked him what his skin care regimen was’Blind date: ‘I really wish I asked him what his skin care regimen was’
bostonglobe.com - May 10 at 7:31 AM
The Best Skin Care Products for Amazing Younger-Looking SkinThe Best Skin Care Products for Amazing Younger-Looking Skin
msn.com - May 10 at 7:31 AM
I’m a Beauty Editor, and This Blurring Skin Tint Is the Best Thing Ive Tried in 2024I’m a Beauty Editor, and This Blurring Skin Tint Is the Best Thing I've Tried in 2024
msn.com - May 10 at 2:31 AM
Is Micellar Water Good for Your Skin? Heres What Beauty Experts SayIs Micellar Water Good for Your Skin? Here's What Beauty Experts Say
msn.com - May 9 at 9:30 PM
15 Best Moisturizers for Acne-Prone Skin, Tested and Reviewed for 202415 Best Moisturizers for Acne-Prone Skin, Tested and Reviewed for 2024
msn.com - May 9 at 9:30 PM
Is Your Skin Barrier Compromised? Here’s How To TellIs Your Skin Barrier Compromised? Here’s How To Tell
msn.com - May 9 at 9:30 PM
BeautyHealth (NASDAQ:SKIN) Beats Q1 Sales Targets But Quarterly Guidance UnderwhelmsBeautyHealth (NASDAQ:SKIN) Beats Q1 Sales Targets But Quarterly Guidance Underwhelms
finance.yahoo.com - May 9 at 9:30 PM
Heres What Key Metrics Tell Us About Beauty Health (SKIN) Q1 EarningsHere's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings
zacks.com - May 9 at 7:31 PM
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue EstimatesThe Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - May 9 at 7:11 PM
BeautyHealth Reports First Quarter 2024 Financial ResultsBeautyHealth Reports First Quarter 2024 Financial Results
businesswire.com - May 9 at 4:05 PM
Skin care tips: Expert-approved diet and lifestyle adjustments to keep your skin glowingSkin care tips: Expert-approved diet and lifestyle adjustments to keep your skin glowing
moneycontrol.com - May 9 at 8:35 AM
Yogurt: What Nutrition Professionals Say About Its Health Effects And MoreYogurt: What Nutrition Professionals Say About Its Health Effects And More
msn.com - May 9 at 3:35 AM
Makeup lovers praise blurring skin tint thats full of anti-ageing ingredientsMakeup lovers praise 'blurring' skin tint that's full of anti-ageing ingredients
msn.com - May 8 at 5:05 PM
Unlocking Personalized Beauty: The Rise of the Global Customized Skincare Market; Published by TNR, The Niche ResearchUnlocking Personalized Beauty: The Rise of the Global Customized Skincare Market; Published by TNR, The Niche Research
finance.yahoo.com - May 8 at 5:05 PM
Neutrogena Lost Dermatologists and Missed Out on the $42 Billion Beauty BoomNeutrogena Lost Dermatologists and Missed Out on the $42 Billion Beauty Boom
msn.com - May 8 at 9:52 AM
Tweens are obsessed with skin care. Experts share dos and dontsTweens are obsessed with skin care. Experts share do's and don'ts
msn.com - May 8 at 9:52 AM
Therapie Clinic rolls out trending polynucleotides skin treatmentTherapie Clinic rolls out trending polynucleotides skin treatment
msn.com - May 8 at 4:52 AM
Here’s What Getting a Skin Patch Test Is Really LikeHere’s What Getting a Skin Patch Test Is Really Like
msn.com - May 7 at 11:51 PM
CLn Skin Care Expands Medical Advisory BoardCLn Skin Care Expands Medical Advisory Board
finance.yahoo.com - May 7 at 6:50 PM
She created oils and herbs for healthy hair and skin. Soon you can buy them in ColumbusShe created oils and herbs for healthy hair and skin. Soon you can buy them in Columbus
yahoo.com - May 7 at 6:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

NASDAQ:INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Luminex logo

Luminex

NASDAQ:LMNX
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Silk Road Medical logo

Silk Road Medical

NASDAQ:SILK
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Beauty Health logo

Beauty Health

NASDAQ:SKIN
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.